Nasal Drug Delivery

This conference gives a comprehensive review within the field of nasal drug delivery while reviewing interesting new data and innovative technologies.

11-12 Apr 2019

GBP 1,499
EUR 2,099
USD 2,338

Book now

Conference overview

How difficult is it to bring all these products to market? What makes nasal delivery systems more challenging than solid dosage forms? How safe is nasal drug delivery? Are there such things as safe excipients? How does all this fit within the regulatory environment in Europe and the USA? This conference seeks to explore these and other questions within the field of nasal drug delivery while reviewing interesting new data and innovative technologies. Leading authorities in nasal drug delivery will cover relevant aspects of nasal physiology, anatomy, absorption of a variety of drugs, in various phases of drug development, and new drugs entering the market. In addition, the conference will discuss nasal delivery to the sinuses and interesting case histories.

Your next step is to call us now on +44 (0)20 7749 4730 or email us at or use our contact form and find out how we can help. There are no commitments, and if we cannot help our advice and recommendations are free of charge.

Please note that this programme relates to the 2018 event and the 2019 brochure and programme will be available in due course.

If you would like to contribute a presentation at the 2019 event please contact

Who should attend

Managing directors, medical directors, head of regulatory affairs and quality assurance, senior executives in research and development, registration, marketing and all departments that may be involved in nasal drug delivery, or who wish to understand the potential of this alternative therapeutic route. Those already involved in Nasal Drug Delivery will benefit from updating their knowledge and sharing experiences with some of the leading practitioners in this field. If you are involved in nasal drug delivery or are just considering the potential, this conference is an excellent route to understanding all aspects from the basic physiology through to launching a successful product.

Three reasons to attend

1. Gain an update on the very latest scientific developments and technology advances in this field.
2. Hear from an unrivalled panel of expert speakers.
3. An excellent networking opportunity to build business relationships.

Programme - Day one


Nasal drugs to treat nasal disorders: a comprehensive review

  • Anatomy and physiology
  • Nasal disorders
  • Treatment options and future prospects to treat allergic and non-allergic Rhinitis
  • Rhinosinusitis and Polyps

Professor Michael S. Benninger, Chairman The Head and Neck Institute, Professor of Surgery, Lerner College of Medicine, The Cleveland Clinic, USA

Nasal drug delivery challenges

  • Discuss ideal attributes of a nasal spray formulation
  • Present strategies to optimize deposition
  • Highlight excipients to facilitate absorption
  • Present technology for delivery and formulation characterization

Dr Julie Suman, President Next Breath, USA

Nasal formulation of drugs

  • Formulation aspects of liquid systems
  • Carrier-based and matrix dry powder formulations for nasal delivery
  • (Nano)particulate drug carriers for nasal administration
  • Interplay of therapeutic targets and nasal deposition

Dr Regina Scherliess, Christian Albrecht University of Kiel, Department of Pharmaceutics and Biopharmaceutics, Germany

Nose to brain drug delivery of Oxytocin

Professor Yannis Paloyelis, Lecturer in Neruoscience and Psychology, Neuroimaging Department, Kings College, UK

Methodology for comparing particle size of nasal spray formulations

David Exline, President, Gateway Analytical, USA

XHANCE™ – A new approach to reach the target sites of inflammation in chronic rhinosinusitis

  • The Exhalation Delivery System (EDS)
  • Reaching the sites of sinus ventilation
  • Accessing the sinuses in the post-surgical patient
  • Clinical outcomes in chronic rhinosinusitis with and without polyps

Dr Per Gisle Djupesland, CSO, OptiNose, Norway

Retronose concept: Aerosol delivery by oral route for nasal drug targeting

  • Proof of concept with nebulization system
  • Differences between oral and nasal routes in terms of nasal deposition distribution
  • Key points for a pMDI development using Retronose concept
  • Pro and Cons for Retronose concept

Pascale Farjas, Global Category Manager – Ear, Nose and Throat, Nemera and Laurent Vecellio, Researcher, INSERM, France

OTC Opportunities & Challenges for Nasal Drug Delivery

Sriman Banerjee, GSK

Drinks reception for delegates and speakers

Programme - Day two


Review of nasal drug delivery devices

  • Trends in nasal delivery systems
  • Advances in device technologies
  • Nasal spray characteristics

Dr René Bommer, General Manager, pharmAccel Consulting, Germany

Advanced water technology: a unique platform for innovative OTC products

  • Is water a simple, innocent molecule?
  • High pH water – a change of paradigm
  • The electrical double layer (EDL) and negative ions
  • Water: from a noble solvent to an innovative active
  • Advanced Water’s unique mechanisms of action
  • How can water make your OTC products smarter?
  • Great opportunities for nasal applications

Georges Bouille, CEO, ADWATISs SA and Jean-Michel Verjus, Pharmacist, ADWATIS SA, Switzerland

FRI as a tool to optimize regional delivery of nasal aerosols

  • What is FRI
  • Challenges of nasal drug delivery
  • Advantages of in-silico clinical trials
  • Evaluating nasal drug efficacy with FRI

Dr Wim Vos, Chief Operating Officer, FLUIDDA, Belgium

Digital healthcare: Improving patient health outcomes through connected devices

  • Challenges with drug adherence and patient health outcomes
  • How connected devices and digital healthcare can make a difference
  • Clinical and commercial

Sai Shankar, Director, Business Development – Connected Devices, Aptar Pharma, France

Qualification of new nasal drug delivery systems for existing drugs

  • Formulation analysis
  • System fit and compatability
  • Stability testing
  • Performance testing
  • Production line and efficiency optimization

Thomas Grinnan, Senior Commercial Director, Healthcare, Silgan Dispensing Systems, France

Aseptic vs non-aseptic filling strategies for nasal spray trends and the evidence behind

  • Different product – different filling strategy
  • Technical and procedural alternatives
  • The role of a Contract Development and Manufacturing Organization

Cecilie Vo, Quality Advisor and Business Development Representative, Curida, Norway

What are Chemisimilars and what’s the problem?

  • Standardisation
  • EU Guidance
  • FDA Guidance
  • Assay sensitivity and the best models to test for similarity

Dr John Warren, Director, Medicines Assessment, UK


Rene Bommer

Dr. René Bommer is a founder and an owner of pharmAccel Consulting.
He received his Ph.D. in Chemistry from the University of Constance in Germany in 1990. After research positions at the Scripps Clinic in San Diego, USA , at Altana Pharma Germany (now Takeda) and a lectureship at the University of Buenos Aires he joined the device developing and manufacturing company Ing. Erich Pfeiffer GmbH in Germany and became a Director of Business Development.
In 2007 René founded a consulting company with a focus on delivery devices. pharmAccel Consulting delivers a service to support an accelerated entry into the market with consideration of technical, regulatory, marketing and pharmaeconomical aspects of the drug delivery device business.

Julie Suman

Dr. Julie D. Suman, R.Ph., Ph.D., is a co-founder and President of Next Breath, LLC, an incubator company located at the UMBC Technology Center. Next Breath, which incorporated in April 2002, is a contract research organisation dedicated to the development of nasal and inhalation delivery systems. She directs the contract research division that supports product development for North American and European clients in the pharmaceutical, biotechnology and medical device markets.
Julie holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). She is a licensed Maryland pharmacist and a member of the Maryland Pharmacy Volunteer Corp.
Julie has also been an affiliate assistant professor in the Department of Pharmaceutics at Virginia Commonwealth University since 2009.

Michael Benninger

Dr. Michael S. Benninger has been the Chairman of the Head and Neck Institute at The Cleveland Clinic since 2008. Previously he was the Chairman of the Department of Otolaryngology-Head and Neck Surgery at Henry Ford Health System in Detroit, Michigan.
He has also been involved in Regional, National and International medical organizations. He served on the Board of Directors of the American Academy of Otolaryngology-Head and Neck Surgery for 12 years, having been a former Vice President and Chairman of the Board of Governors.
Dr. Benninger is on the Board of Directors of the Voice Foundation and the International Association of Phonosurgeons, and has recently been on the Executive Council of the Triological Society.
In addition to his numerous professional pursuits Dr. Benninger has authored 6 books, including his most recent books, “The Performer’s Voice” and “The Singer’s Voice”. He has written over 100 scientific articles, focusing primarily on voice care and laryngology, nasal and sinus disease and health care management. Dr. Benninger has also lectured extensively across the US and throughout the world.

Book now

11-12 Apr 2019
11-12 Apr 2019 Holiday Inn London - Kensington Forum, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Enrol now

You may also be interested in

Previous customers include...

  • Acino Pharma AG
  • Advanex Europe Ltd
  • Archimedes Pharma Ltd
  • Archimedes Pharma UK Limited
  • BOC Medical
  • CDC
  • Critical Pharmaceuticals Limited
  • DCA Design International
  • Emergent BioSolutions
  • Ever Neuro Pharma GmbH
  • Federal Institut for Drug and Medical Devices
  • Interdos Pharma bv
  • Intranasal technology Inc
  • Laboratorios Salvat SA
  • M+P Pharma AG
  • Nemera Services
  • Pharmacosmos A/S
  • Raumedic UK Ltd
  • Rexam Pharma
  • RPC Formatec GmbH
  • Scandinavian Health Ltd Taiwan branch
  • Takeda GmbH
  • University of Gent
  • Valois UK Limited
  • Zentiva Group AS

A great collection of knowledgable speakers

Matthew Burton, , Jenson R+ Ltd


Nicola Hardman, , Jenson R+ Ltd